CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects

Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic treatments are available. Repurposing drugs that target α-synuclein aggregation, considered one of the main drivers of PD progression, could accelerate the development of disease-modifying therapies. In this wor...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Lizárraga, Florencia, Ploper, Diego, Ávila, César L., Socías, Sergio B., dos-Santos-Pereira, Mauricio, Machín, Belén, Del-Bel, Elaine, Michel, Patrick Pierre, Pietrasanta, Lía I., Raisman-Vozari, Rita, Chehín, Rosana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679368/
https://www.ncbi.nlm.nih.gov/pubmed/33219264
http://dx.doi.org/10.1038/s41598-020-76927-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679368/
https://www.ncbi.nlm.nih.gov/pubmed/33219264
http://dx.doi.org/10.1038/s41598-020-76927-0

Ejemplares similares